RhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor defi- ciency. Expert Rev Clin Immunol. 2011;7:143-53.Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert ...
事后分析显示,在接受大量造影剂的PCI亚组患者中,与安慰剂组相比,rhC1INH组的尿NGAL中位绝对峰值和相对峰值明显小于安慰剂组(1.8 ng/ml[IQR:-2.7-12.5] vs.26.2 ng/ml[IQR:16.0-133.8];P=0.039;11%[IQR:-5%-74%] vs.205%[IQR:84%-469%];P=0.002),而在非PCI患者中无明显差异。 次要终点方面,RhC1...
Pharming是一家商业阶段的生物制药公司,专注于于开发蛋白质替代疗法和罕见病的精准治疗。 公司的核心管线RUCONEST®是重组人C1酯酶抑制剂(recombinant human C1 esterase inhibitor,rhC1INH),是第一个也是唯一的无血浆rhC1INH蛋白替代疗法,C1INH是一种天然存在的蛋白质,它可以下调补体的级联反应,从而控制受影响部位的...
Israel, and colleagues examined the safety and prophylactic effect of weekly administration of rhC1INH (50 U/kg body weight) in a study involving 25 patients with a history of HAE attacks occurring at least every two weeks. Following a two-week run-in period, patients received rhC1INH admini...
rcc-rhC1INH 和ox-rhC1INH 2 种对照品质量浓度为0.2、1 和 1.4 mg ·mL-1 时的回收 率均在85%~115% 的范围内。对同1 批3 个待测样品进行测定,rcc-rhC1INH 含量为(0.082 ±0.008 )% , RSD 为9.8% ;ox-rhC1INH 含量为(0.35 ±0.05 )% ,RSD 为14.3%,显示该方法具有较好的专属性、准确性 和...
rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 2011; 7: 143-153.Varga L, Farkas H. RhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1‑inhibitor deficiency....
rhC1INH Cuts Attack Frequency in Hereditary AngioedemaNewsJaapa
(0.082±0.008)%,RSD为9.8%;ox-rhC1INH含量为(0.35±0.05)%,RSD为14.3%,显示该方法具有较好的专属性,准确性和精密度.4批测试样品中,rcc-rhC1INH的含量分别为0.083%,0.021%,0.033%,0.042%,ox-rhC1INH的含量分别为0.34%,0,0,0.结论:经方法学验证,RP-HPLC方法可用于rhC1INH中rcc-rhC1INH和ox-rhC1INH...
Recombinant Human C1 Inhibitor (rHC1INH) Is Efficacious and Well Tolerated As Prophylaxis for Prevention of Hereditary Angioedema (HAE) Attacks: A Randomized, Phase 2 TrialAim: To determine the frequency of diabetic ketoacidosis in diabetic patients presenting in a tertiary care setting and frequency...
Clinical studies of recombinant human Cl inhibitor (rhC1-INH) in patients with acute attacks of hereditary angioedema [abstract]. J Allergy Clin Immunol 2008; 121(3): 797Nuijens J, Verdonk R, Giannetti B, Visscher S, van Doorn M, Resink T, et al. Clin- ical studies of recombinant ...